US Medicare should use cost-effectiveness more in decision-making
This article was originally published in Clinica
Medicare officials could play an important role in advancing the field of cost effectiveness, an influential advisory group told Congress yesterday. Current studies vary in the methods used to compare the relative costs of one medical product to another, the Medicare Payment Advisory Commission (MedPAC) pointed out.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.